Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia.
BACKGROUND
A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted.


METHODS
Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m2 given as a continuous 24-h intravenous infusion repeated every 3-4 weeks.


RESULTS
Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias.


CONCLUSIONS
The study paclitaxel regimen was ineffective in refractory adult ALL.
Colburn
Dawn E
DE
Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Thomas
Deborah A
DA
Giles
Francis J
FJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel